Dr. Nathan Bryan
speaker
1,178 appearances
5 recordings
3 series
first heard Feb 2025
last heard 3 Apr
Dr. Nathan Bryan’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 3 in all, peaking in Apr 2026 with 1.
Appearances
Again, 50% of the patients that are treated with prescription medication don't respond with better blood pressure. That's a huge problem because high blood pressure is the number one driver of cardiovascular disease, which is the number one killer of men and women worldwide. Number three, metabolic disease and diabetes.
We published in 2011 that nitric oxide production is necessary for insulin signaling. If the cell can't make nitric oxide, you develop insulin resistance. So diabetes, a global pandemic. Nine out of ten Americans are metabolically unfit. The other thing is exercise intolerance.
If you try to start an exercise regimen and you can't walk up a flight of steps or exercise moderately for 15, 20, 30 minutes, then you're nitric oxide deficient. And then the other one is obviously Alzheimer's because Alzheimer's is a vascular disease. It's reduced blood flow to the brain, what we call focal ischemia. There's insulin resistance. Alzheimer's has been called diabetes type 3.
So you can't get glucose into the cell, and that's the primary energy source or substrate of the brain. Oxidative stress and immune dysfunction. And then you get misfolded proteins, and that shows up as the tau tangles and the amyloid plaque that we see in Alzheimer's patients. So if we can restore—and nitric oxide corrects every single thing we know about Alzheimer's.
It improves blood flow to the brain. It improves glucose uptake, so it overcomes the metabolic aspect of Alzheimer's. It reduces inflammation. In fact, a number of my patents are on a method of reducing inflammation. It inhibits the oxidative stress we see in Alzheimer's and neurological disease, and it prevents the immune dysfunction.
And when you do that, when you restore blood flow and you get nutrients and oxygen in and you take out the metabolic waste products, there's no misfolding of protein. So you don't get the amyloid plaque. You don't get the tau tangles. So this simple molecule, nitric oxide gas, I'm absolutely convinced will eradicate and cure Alzheimer's.
Because it addresses every physiological root cause of Alzheimer's.
No, I think that's a very key because the success or failure of any clinical trial, any drug in any clinical trial is dependent upon the design of the clinical trial and what patients at what stage of disease that you enroll these patients. So what are the inclusion criteria and what are the exclusion criteria?
And there's a stage in every disease, whether it's heart disease, kidney disease, Alzheimer's, where you've reached a point of no return. There's really no medical therapy that's going to reverse that disease because it's progressed to a state that's irreversible.
So I think what we try to do is take patients early in the process, what we call vascular dementia, mild cognitive impairment, early Alzheimer's. Because what I want to be able to demonstrate is two things. Number one, can we stop the progression of disease? Once it's started, can we stop the progression?
And then number two is we want to enroll patients far enough along to where we can show regression. So can you move the needle back? And so that's a very kind of a specific and finite patient population. When you design a clinical study, number one, at the absolute worst, we want to stop progression. At the absolute best, we want to show that we can regress disease.
And that's the goal of therapy, is that you understand the mechanism of disease to the extent that you can treat it, you can prevent it, you can reverse it, and you can cure it.
I believe in the truth, and I come from a very objective scientific background, so everything that we do is based on objective data.
No, absolutely, because, you know, we talk about epiphanies and eureka moments in science. But for me, one of the kind of complete change in paradigm in the way that I think was changed when I was in academia and teaching in medical school and doing research in an academic institution. And you start to think, in the scientific community, we've cured every disease.
Every disease known to man, we've cured it in rats and mice. So then the question is, why isn't this translated into patient care? Why can't we do this in humans? Number one, in animal experiments, we control their environment. We control their food. We control their light cycle. We control everything about them. You can't do that. Everybody has a different diet.
Everybody has different drug therapy that they're on or hygienic practices. But then what I realized was because when I was in academia, we wanted to create this consortium, a center of excellence for diseases, because my thought process was, you know, Western medicine is siloed, right? If you have a heart problem, you go to a cardiologist.
If you've got a GI problem, you go to a gastroenterologist. If you've got a neurological problem, you go to a neurologist or psychiatrist. But none of these disciplines talk to one another. So if you go to, that neurologist is going to treat that condition much different than the cardiologist would, much different than the GI doc would. But what if we're looking at the exact same root cause?
And so my philosophy, well, let's create a center of excellence and let's bring everybody in the room. Let's bring the GI docs, the neurologist, the cardiologist, the geneticist, the pulmonary docs, the kidney docs, the renal docs. And let's understand this kind of wheel and cog because everything occurs at the mitochondria, subcellular level, and energy production.
And then basically everything can manifest from that. But what I quickly realized when you go to, for instance, MD Anderson and trying to treat cancer, no one is interested in curing cancer. No one is interested in curing human disease. Because the epiphany for me came because medicine is a business. It's a for-profit business.
In fact, it's the largest business and economic model in the world, trillion-dollar annualized market. And most of these drug companies who influence and pay and support scientific journals, JAMA, New England Journal of Medicine, the major publications, the major journals, and they're influencing regulation and policy and FDA.
Showing 761–780 of 1,178 · page 39 of 59
← Previous
Next →